Prezista

Product manufactured by Janssen Products Lp

Application Nr Approved Date Route Status External Links
NDA021976 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Prezista ® , Co-Administered With Ritonavir (Prezista/ritonavir), In Combination With Other Antiretroviral Agents, Is Indicated For The Treatment Of Human Immunodeficiency Virus (Hiv-1) Infection In Adult And Pediatric Patients 3 Years Of Age And Older [See Use In Specific Populations (8.4) And Clinical Studies (14) ] . Prezista Is A Human Immunodeficiency Virus (Hiv-1) Protease Inhibitor Indicated For The Treatment Of Hiv-1 Infection In Adult And Pediatric Patients 3 Years Of Age And Older. Prezista Must Be Co-Administered With Ritonavir (Prezista/ritonavir) And With Other Antiretroviral Agents. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Darunavir Ethanolate DARUNAVIR ETHANOLATE ZINC3955219

Comments